Macbery Oral Drops contain a combination of Levosalbutamol (0.25 mg) and Ambroxol (7.5 mg), formulated to provide effective relief in respiratory conditions characterized by bronchospasm and excessive mucus production. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating easier breathing and reducing wheezing and shortness of breath. Ambroxol serves as a mucolytic agent, promoting the breakdown and clearance of mucus from the respiratory tract, which enhances expectoration and improves airway patency. This dual-action formulation is particularly beneficial in managing conditions such as asthma, chronic bronchitis, and other obstructive airway diseases where both bronchoconstriction and mucus hypersecretion are present. Macbery Oral Drops are administered orally, allowing for rapid systemic absorption and prompt therapeutic effect. The dosage should be tailored according to the patient’s age, severity of symptoms, and clinical response, under medical supervision. Common side effects may include mild gastrointestinal discomfort or tremors, which are generally transient. Caution is advised in patients with cardiovascular disorders or hypersensitivity to any component. Macbery Oral Drops offer a synergistic approach to respiratory symptom management, improving patient comfort and respiratory function.